Millennium Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-14,130
Closed -$3K 4479
2018
Q1
$3K Buy
+14,130
New +$13K ﹤0.01% 3580
2017
Q1
Sell
-15,823
Closed -$28K 4162
2016
Q4
$28K Sell
15,823
-25,912
-62% -$60.9K ﹤0.01% 3272
2016
Q3
$139K Sell
41,735
-23,665
-36% -$89.4K ﹤0.01% 3068
2016
Q2
$281K Buy
65,400
+60,422
+1,214% +$273K ﹤0.01% 2763
2016
Q1
$28K Sell
4,978
-343,773
-99% -$4.46M ﹤0.01% 3187
2015
Q4
$6M Sell
348,751
-45,246
-11% -$1.08M 0.01% 1239
2015
Q3
$8.31M Sell
393,997
-70,533
-15% -$2.42M 0.02% 1038
2015
Q2
$23M Buy
464,530
+239,760
+107% +$14.3M 0.04% 563
2015
Q1
$17.6M Buy
224,770
+130,217
+138% +$8.08M 0.03% 728
2014
Q4
$5.73M Buy
+94,553
New +$4.75M 0.01% 1299
2014
Q3
Sell
-19,078
Closed -$1.18M 4376
2014
Q2
$1.18M Sell
19,078
-185,879
-91% -$10.8M ﹤0.01% 2106
2014
Q1
$13.3M Sell
204,957
-44,944
-18% -$3.04M 0.04% 640
2013
Q4
$14.1M Buy
249,901
+219,390
+719% +$12.3M 0.04% 518
2013
Q3
$1.87M Buy
30,511
+28,406
+1,349% +$1.92M 0.01% 1728
2013
Q2
$123K Buy
+2,105
New +$130K ﹤0.01% 2846

Other funds holding OREX

Millennium Management's OREX Position: Q2 2018 in Review

Millennium Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 14,130 shares — an estimated $3K sold.

Millennium Management first reported a position in OREX in Q2 2013 and held it in 15 quarters. The position peaked at $23M in Q2 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

  • Millennium Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Millennium Management sold 14,130 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $3K.
  • Millennium Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
  • Millennium Management's Orexigen Therapeutics, Inc. position peaked at $23M in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Millennium Management's 13F filing for Q2 2018, filed 14 Aug 2018.